Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Transplantation. 2012 Oct 15;94(7):687-94. doi: 10.1097/TP.0b013e3182633478.
Small-for-size syndrome (SFSS) may occur when graft volume is less than 45% of the standard liver volume, and it manifests as retarded growth and failure of the grafts and more mortality. However, its pathogenesis is poorly understood, and few effective interventions have been attempted.
The present study aimed to delineate the critical role of oxidant stress in SFSS and protective effects of a superoxide dismutase mimetic, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP), on graft function, growth, and survival in the recipient rats.
Small size graft liver transplantation (SSGLT) was performed to determine the survival, graft injury, and growth. MnTBAP was administered in SSGLT recipients (SSGLT+MnTBAP).
Serum alanine aminotransferase levels were sustained higher in SSGLT recipients, which were correlated with an increased apoptotic cell count and hepatocellular necrosis in liver sections. Malondialdehyde content, gene expression of tumor necrosis factor α and interleukin 1β, and DNA binding activity of nuclear factor-κB in the grafts were increased significantly in SSGLT recipients compared with sham-operated controls. Both phosphorylated p38 mitogen-activated protein kinase and nuclear c-Jun were increased in SSGLT. All these changes were strikingly reversed by the administration of MnTBAP, with an increase in serum superoxide dismutase activity. Moreover, in situ bromodeoxyuridine incorporation demonstrated that graft regeneration was much more profound in the SSGLT+MnTBAP group than in the SSGLT group. Finally, the survival of recipients with MnTBAP treatments was significantly improved.
Enhanced oxidant stress with activation of the p38/c-Jun/nuclear factor-κB signaling pathway contributes to SFSS-associated graft failure, retarded graft growth, and poor survival. MnTBAP effectively reversed the pathologic changes in SFSS-associated graft failure.
当移植物体积小于标准肝体积的 45%时,可能会发生小肝综合征(SFSS),表现为移植物生长迟缓、衰竭和更高的死亡率。然而,其发病机制尚不清楚,尝试的干预措施也很少。
本研究旨在阐明氧化应激在 SFSS 中的关键作用,以及超氧化物歧化酶模拟物 Mn(III)四(4-苯甲酸)卟啉氯化物(MnTBAP)对受体大鼠移植物功能、生长和存活的保护作用。
进行小尺寸供肝肝移植(SSGLT)以确定存活率、移植物损伤和生长。在 SSGLT 受者中给予 MnTBAP(SSGLT+MnTBAP)。
SSGLT 受者的血清丙氨酸氨基转移酶水平持续升高,与肝组织中凋亡细胞计数增加和肝细胞坏死相关。与假手术对照组相比,SSGLT 受者的丙二醛含量、肿瘤坏死因子α和白细胞介素 1β的基因表达以及核因子-κB 的 DNA 结合活性均显著增加。SSGLT 中磷酸化 p38 丝裂原活化蛋白激酶和核 c-Jun 均增加。MnTBAP 的给予显著逆转了所有这些变化,同时血清超氧化物歧化酶活性增加。此外,原位溴脱氧尿苷掺入表明,SSGLT+MnTBAP 组的移植物再生比 SSGLT 组更为明显。最后,MnTBAP 治疗的受者存活率显著提高。
增强的氧化应激激活 p38/c-Jun/核因子-κB 信号通路导致与 SFSS 相关的移植物衰竭、移植物生长迟缓和预后不良。MnTBAP 可有效逆转与 SFSS 相关的移植物衰竭的病理变化。